Shares of Check Cap Ltd (NASDAQ:CHEK) have been given a consensus broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company. Check Cap’s rating score has declined by 50% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a twelve-month consensus price target of $10.50 for the company and are anticipating that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 101 out of 255 based on the ratings given to related companies.
Several research firms have recently commented on CHEK. HC Wainwright set a $14.00 target price on Check Cap and gave the company a “buy” rating in a report on Friday, December 14th. Zacks Investment Research lowered shares of Check Cap from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Dougherty & Co assumed coverage on shares of Check Cap in a research note on Tuesday, February 5th. They issued a “buy” rating and a $6.00 price target on the stock.
Shares of NASDAQ:CHEK remained flat at $$2.70 during trading on Friday. The stock had a trading volume of 657 shares. The company has a market capitalization of $4.32 million and a price-to-earnings ratio of -1.03. Check Cap has a 52 week low of $1.62 and a 52 week high of $19.78.
Check Cap (NASDAQ:CHEK) last posted its earnings results on Thursday, March 28th. The medical research company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.04). On average, equities research analysts predict that Check Cap will post -1.7 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Check Cap stock. Dimensional Fund Advisors LP acquired a new stake in shares of Check Cap Ltd (NASDAQ:CHEK) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 35,131 shares of the medical research company’s stock, valued at approximately $141,000. Dimensional Fund Advisors LP owned 2.20% of Check Cap at the end of the most recent quarter.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Read More: Gross Domestic Product (GDP)
Get a free copy of the Zacks research report on Check Cap (CHEK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.